138 related articles for article (PubMed ID: 34373117)
1. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
Eldridge JH; Egan MA; Matassov D; Hamm S; Hermida L; Chen T; Tremblay M; Sciotto-Brown S; Xu R; Dimitrov A; Smith ER; Gurwith M; Chen RT;
Vaccine; 2021 Sep; 39(38):5436-5441. PubMed ID: 34373117
[TBL] [Abstract][Full Text] [Related]
2. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Kochhar S; Kim D; Excler JL; Condit RC; Robertson JS; Drew S; Whelan M; Wood D; Fast PE; Gurwith M; Klug B; Khuri-Bulos N; Smith ER; Chen RT;
Vaccine; 2020 Jul; 38(35):5734-5739. PubMed ID: 32653276
[TBL] [Abstract][Full Text] [Related]
3. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge.
Pallister J; Middleton D; Wang LF; Klein R; Haining J; Robinson R; Yamada M; White J; Payne J; Feng YR; Chan YP; Broder CC
Vaccine; 2011 Aug; 29(34):5623-30. PubMed ID: 21689706
[TBL] [Abstract][Full Text] [Related]
4. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Condit RC; Kim D; Robertson JS; Excler JL; Gurwith M; Monath TP; Pavlakis G; Fast PE; Smith J; Smith ER; Chen RT; Kochhar S;
Vaccine; 2020 Nov; 38(49):7708-7715. PubMed ID: 32907759
[TBL] [Abstract][Full Text] [Related]
5. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Gurwith M; Condit RC; Excler JL; Robertson JS; Kim D; Fast PE; Drew S; Wood D; Klug B; Whelan M; Mallett Moore T; Khuri-Bulos N; Smith ER; Chen RT; Kochhar S;
Vaccine; 2020 Nov; 38(49):7702-7707. PubMed ID: 33070999
[TBL] [Abstract][Full Text] [Related]
6. Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials.
Rodrigue V; Gravagna K; Yao J; Nafade V; Basta NE
Trop Med Int Health; 2024 May; 29(5):354-364. PubMed ID: 38415314
[TBL] [Abstract][Full Text] [Related]
7. A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.
Mire CE; Geisbert JB; Agans KN; Feng YR; Fenton KA; Bossart KN; Yan L; Chan YP; Broder CC; Geisbert TW
J Virol; 2014 May; 88(9):4624-31. PubMed ID: 24522928
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters.
Lo MK; Spengler JR; Welch SR; Harmon JR; Coleman-McCray JD; Scholte FEM; Shrivastava-Ranjan P; Montgomery JM; Nichol ST; Weissman D; Spiropoulou CF
J Infect Dis; 2020 May; 221(Suppl 4):S493-S498. PubMed ID: 31751453
[TBL] [Abstract][Full Text] [Related]
9. A treatment for and vaccine against the deadly Hendra and Nipah viruses.
Broder CC; Xu K; Nikolov DB; Zhu Z; Dimitrov DS; Middleton D; Pallister J; Geisbert TW; Bossart KN; Wang LF
Antiviral Res; 2013 Oct; 100(1):8-13. PubMed ID: 23838047
[TBL] [Abstract][Full Text] [Related]
10. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Kochhar S; Excler JL; Kim D; Robertson JS; Fast PE; Condit RC; Drew S; Wood D; Gurwith M; Klug B; Whelan M; Khuri-Bulos N; Mallett Moore T; Smith ER; Chen RT;
Vaccine; 2020 Sep; 38(39):6184-6189. PubMed ID: 32747214
[TBL] [Abstract][Full Text] [Related]
11. Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice.
Li Y; Li R; Wang M; Liu Y; Yin Y; Zai X; Song X; Chen Y; Xu J; Chen W
Viruses; 2020 Apr; 12(4):. PubMed ID: 32340278
[TBL] [Abstract][Full Text] [Related]
12. Rhabdovirus-based vaccine platforms against henipaviruses.
Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
[TBL] [Abstract][Full Text] [Related]
13. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Kim D; Robertson JS; Excler JL; Condit RC; Fast PE; Gurwith M; Pavlakis G; Monath TP; Smith J; Wood D; Smith ER; Chen RT; Kochhar S;
Vaccine; 2020 Jul; 38(34):5556-5561. PubMed ID: 32571717
[TBL] [Abstract][Full Text] [Related]
14. Vaccines to Emerging Viruses: Nipah and Hendra.
Amaya M; Broder CC
Annu Rev Virol; 2020 Sep; 7(1):447-473. PubMed ID: 32991264
[TBL] [Abstract][Full Text] [Related]
15. Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.
Defang GN; Khetawat D; Broder CC; Quinnan GV
Vaccine; 2010 Dec; 29(2):212-20. PubMed ID: 21050901
[TBL] [Abstract][Full Text] [Related]
16. Hendra virus and Nipah virus animal vaccines.
Broder CC; Weir DL; Reid PA
Vaccine; 2016 Jun; 34(30):3525-34. PubMed ID: 27154393
[TBL] [Abstract][Full Text] [Related]
17. Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes.
Bradel-Tretheway BG; Zamora JLR; Stone JA; Liu Q; Li J; Aguilar HC
J Virol; 2019 Jul; 93(13):. PubMed ID: 30971473
[TBL] [Abstract][Full Text] [Related]
18. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
Leav B; Straus W; White P; Leav A; Gaines T; Maggiacomo G; Kim D; Smith ER; Gurwith M; Chen RT;
Vaccine; 2022 Aug; 40(35):5275-5293. PubMed ID: 35753841
[TBL] [Abstract][Full Text] [Related]
19. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection.
Yun T; Park A; Hill TE; Pernet O; Beaty SM; Juelich TL; Smith JK; Zhang L; Wang YE; Vigant F; Gao J; Wu P; Lee B; Freiberg AN
J Virol; 2015 Jan; 89(2):1242-53. PubMed ID: 25392218
[TBL] [Abstract][Full Text] [Related]
20. Hendra and Nipah infection: emerging paramyxoviruses.
Aljofan M
Virus Res; 2013 Nov; 177(2):119-26. PubMed ID: 23954578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
